)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Ceryvyn Therapeutics
Ceryvyn Therapeutics (CYV) investor relations material
Ceryvyn Therapeutics Q1 2027 TU earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 2027 TU earnings summary28 Oct, 2026
Executive summary
CYV-101 Stage 1 LAM preclinical biology and inhalation work continued; nebulisation feasibility and preliminary animal safety and tolerability studies remain on track.
Planned clinical development advanced through a Polarian Xe-MRI agreement, Stage 2 CRO selection after quarter-end, patient engagement planning and the inaugural Scientific Advisory Board meeting.
Financial highlights
Cash and equivalents were AUD $27.463m at 30 September 2026, down from AUD $30.021m at 30 June 2026; operating cash outflow was AUD $2.364m.
Operating cash outflow increased from AUD $1.1m in the previous quarter; interest income was AUD $0.3m.
Cash flow included a negative AUD $194k foreign-exchange movement; quarter-end cash comprised AUD $3.915m in bank balances and AUD $23.548m in call deposits.
Outlook and guidance
Stage 1 preclinical biology and inhalation studies are underway; progression between the three development stages depends on predefined scientific, operational and capital allocation criteria reviewed by the Board.
The selected Australian-based CRO is expected to support Stage 2 protocol development, ethics submissions, site feasibility, nebulised dosing materials, safety monitoring and data services; scope and budget will be refined as study requirements are confirmed.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Ceryvyn Therapeutics
- Repurposing OPT-302 for LAM targets a rare disease market with high unmet need and strong commercial logic.CYV
Corporate presentation - OPT-302 targets LAM with a capital-efficient, stage-gated rare disease strategy and strong leadership.CYVInvestor presentation
- Returned to profitability with A$330.4 million profit after DFA settlement and strategic reset.CYVH2 2026
- Advancing OPT-302 for LAM with robust funding, expert leadership, and a focused rare disease strategy.CYVInvestor update
- Cash reserves at AUD $31.2M, LAM program underway, ASX reinstatement targeted in H1 2026.CYVQ3 2026 TU
- Phase 3 wet AMD trials fully enrolled; cash runway extended through 2025 topline data.CYVH2 2024
- Profit surges on DFA settlement as focus shifts to LAM, with cash reserves funding near-term plans.CYVH1 2026
- Sozinibercept shows superior efficacy in wet AMD and nears pivotal phase III results in 2025.CYVH.C. Wainwright 4th Annual Ophthalmology Virtual Conference
- Net loss reached US$131.9M as cash runway supports pivotal trials amid funding uncertainty.CYVH1 2025
Next Ceryvyn Therapeutics earnings date
H1 202727 Feb, 2027
Ceryvyn Therapeutics
Next Ceryvyn Therapeutics earnings date
H1 202727 Feb, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Opthea Limited is a clinical-stage biopharmaceutical company based in Australia, specializing in the development and commercialization of innovative therapies primarily for eye diseases. The company's primary focus is on advancing its intellectual property portfolio, which encompasses Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3. These are aimed to be used in treating diseases associated with blood and lymphatic vessel growth as well as vascular leakage. The company is headquartered in South Yarra, Victoria, Australia, and its shares are listed on the NASDAQ and ASX.